eISSN: 1644-4116
ISSN: 1429-8538
Psychoonkologia
Bieżący numer Archiwum Artykuły zaakceptowane O czasopiśmie Bazy indeksacyjne Prenumerata Kontakt Zasady publikacji prac
NOWOŚĆ
Portal dla onkologów!
www.eonkologia.pl
2/2014
vol. 18
 
Poleć ten artykuł:
Udostępnij:
więcej
 
 
streszczenie artykułu:
Artykuł przeglądowy

Jakość życia chorych na raka jajnika

Joanna Kozaka

Psychoonkologia 2014, 2: 66–72
Data publikacji online: 2014/09/15
Pełna treść artykułu
Pobierz cytowanie
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Raki jajnika zajmują wysoką pozycję wśród nowotworów ginekologicznych pod względem częstości zachorowań i zgonów. U większości kobiet choroba zostaje zdiagnozowana w zaawansowanym stadium. Stosowane chirurgiczne zabiegi cytoredukcyjne i uzupełniająca chemioterapia wiążą się z wieloma objawami niepożądanymi. Obciążająca emocjonalnie choroba i jej leczenie znacząco wpływają na pogorszenie jakości życia. W pracy przedstawiono specyfikę jakości życia tej grupy chorych i skupiono się na aspektach niepłodności, przedwczesnej menopauzy, obrazu ciała i kobiecości, funkcjonowania seksualnego, dystresu, zmęczenia, a także objawach niepożądanych chemioterapii.

Share of ovarian cancer in gynecological cancers is high in terms of frequency of cancer cases and deaths. Majority of cases are recognized in an advanced stage of disease. Cytoreductive surgery and followed chemotherapy are associated with side effects. This emotionally aggravating disease and its treatment significantly affects deterioration in the quality of life. The paper illustrates the specificity of the quality of life for this group of patients and focuses on aspects of infertility, treatment-induced menopause, body image and femininity, sexual functioning, distress, fatigue, and also on side effects of chemotherapy.
słowa kluczowe:

rak jajnika, jakość życia

referencje:
Kornafel J, Mądry R, Bidziński M i wsp. Nowotwory kobiecego układu płciowego. W: Krzakowski M, Warzocha K (red.). Onkologia w praktyce klinicznej. Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych. Tom I. Via Medica, Gdańsk 2013; 265-317. 
Zieliński J, Krzakowski M. Nowotwory złośliwe narządu płciowego kobiety. W: Krzakowski M (red.). Onkologia kliniczna. Tom II. Wydawnictwo Medyczne Borgis, Warszawa 2001; 140-193. 
Markowska J. Epidemiologia raka jajnika. W: Markowska J (red.). Rak jajnika. Springer PWN, Warszawa 1997; 9-16. 
Mangone L, Mandato VD, Gandolfi R, Tromellini C, Abrate M. The impact of epithelial ovarian cancer diagnosis on women’s life: a qualitative study. Eur J Gynaecol Oncol 2014; 35: 32-38. 
Roland KB, Rodriguez JL, Patterson JR, Trivers KF. A literature review of the social and psychological needs of ovarian cancer survivors. Psychooncology 2013; 22: 2408-2418. 
Donovan KA, Donovan HS, Cella D i wsp. Recommended patient-reported core set of symptoms and quality-of-life domains to measure in ovarian cancer treatment trials. J Natl Cancer Inst 2014; 106. doi: 10.1093/jnci/dju128. 
Carmack Taylor CL, Basen-Engquist K, Shinn EH, Bodurka DC. Predictors of sexual functioning in ovarian cancer patients. J Clin Oncol 2004; 22: 881-889. 
Stewart DE, Wong F, Duff S, Melancon CH, Cheung AM. “What doesn’t kill you makes you stronger”: an ovarian cancer survivor survey. Gynecol Oncol 2001; 83: 537-542. 
Tabano M, Condosta D, Coons M. Symptoms affecting quality of life in women with gynecologic cancer. Seminar Oncol Nurs 2002; 18: 223-230. 
Carter J, Rowland K, Chi D i wsp. Gynecologic cancer treatment and the impact of cancer-related infertility. Gynecol Oncol 2005; 97: 90-95. 
Wenzel L, Dogan-Ates A, Habbal R i wsp. Defining and measuring reproductive concers of female cancer survivors. J Nat Cancer Inst Monogr 2005; 34: 94-98. 
Fitch MI. Gynecologic cancer. W: Holland J, Breitbart WS, Jacobsen PB, Lederberg MS, Loscalzo MJ, McCorkle R (red.). Psycho-Oncology. Oxford University Press, New York 2010; 167-171. 
Graziottin A, Basson R. Sexual dysfunction in women with premature menopause. Menopause 2004; 11, 6 Pt 2: 766-777. 
Muszyńska-Wiese E, Wilkoszarska J. Jakość życia chorych na raka jajnika. W: Markowska J (red.). Rak jajnika. Springer PWN, Warszawa 1997; 183-188. 
Andersen BL, Woods XA, Copeland LJ. Sexual self-schema and sexual morbidity among gynecologic cancer survivors. J Consult Clin Psychol 1997; 65: 221-229. 
Roth AJ, Carter J, Nelson ChJ. Sexuality after cancer. W: Holland J, Breitbart WS, Jacobsen PB, Lederberg MS, Loscalzo MJ, McCorkle R (red.). Psycho-Oncology. Oxford University Press, New York 2010; 245-250. 
Turan V, Oktay K. Sexual and fertility adverse effects associated with chemotherapy treatment in women. Expert Opin Drug Saf 2014; 13: 775-783. 
Wenzel LB, Donnelly JP, Fowler JM i wsp. Resilience, reflection, and residual stress in ovarian cancer survivorship: a gynecologic oncology group study. Psychooncology 2002; 11: 142-153. 
Rieger E, Touyz SW, Wain GV. The role of the clinical psychologist in gynecological cancer. J Psychosom Res 1998; 45: 201-214. 
Ganz PA, Desmond KA, Belin TR, Meyerowitz BE, Rowland JH. Predictors of sexual health in women after a breast cancer diagnosis. J Clin Oncol 1999; 17: 2371-2380. 
Kornblith AB, Thaler HT, Wong G i wsp. Quality of life of women with ovarian cancer. Gynecol Oncol 1995; 59: 231-242. 
Bodurka-Bevers DC, Basen-Engquist K, Carmack CL i wsp. Depression, anxiety, and quality of life in patients with epithelial ovarian cancer. Gynecol Oncol 2000; 78: 302-308. 
Harter P, Schrof I, Karl LM i wsp. Sexual Function, Sexual Activity and Quality of Life in Women with Ovarian and Endometrial Cancer. Gebursthilfe Freuenheilkd 2013; 73: 428-432. 
Hallowell N. “You don’t want lose your ovaries because you think »I might become a man«”. Psychooncology 1998; 7: 263-275. 
Bowes DE, Tamlyn D, Butler LJ. Women living with ovarian cancer: dealing with an Elary Heath. Health Care Women Int 2002; 23: 135-148. 
Clevenger L, Schrepf A, Degeest K i wsp. Sleep disturbance, distress, and quality of life in ovarian cancer patients during the first year after diagnosis. Cancer 2013; 119: 3234-3241. 
Howell D, Fitch MI, Deane KA. Impact of ovarian cancer perceived by women. Cancer Nurs 2003; 26: 1-9. 
Portenoy RK, Thaler HT, Kornblith AB i wsp. Symptom prevalence, characteristics and distress in a cancer population. Qual Life Res 1994; 3: 183-189. 
Norton TR, Manne SL, Rubin S i wsp. Prevalence and predictors of psychological distress among women with ovarian cancer. J Clin Oncol 2004; 22: 919-926. 
Ferrrell B, Smith SL, Cullinane CA, Melancon C. Psychological well being and quality of life in ovarian cancer survivors. Cancer 2003; 98: 1061-1071. 
Hamilton AB. Psychological aspects of ovarian cancer. Cancer Invest 1999; 17: 335-341. 
de Moor JS, de Moor CA, Basen-Engquist K, Kudelka A, Bevers MW, Cohen L. Optimism, distress, health-related quality of life, and change in cancer antigen 125 among patients with ovarian cancer undergoing chemotherapy. Psychosom Med 2006; 68: 555-562. 
Wenzel L, Huang HQ, Monk BJ, Rose PG, Cella D. Quality-of-life comparison in a randomized trial of interval secondary cytoreduction in advanced ovarian carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 2005; 23: 5605-5612. 
Sun CC, Bodurka DC, Donato ML i wsp. Patients preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time? Gynecol Oncol 2002; 87: 118-128. 
Sun CC, Bodurka DC, Weaver CB i wsp. Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. Support Care Cancer 2005; 13: 219-227. 
Kim Y, Morrow GR. Changes in family relationships affect the development of chemotherapy-related nausea symptoms. Support Care Cancer 2003; 11: 171-177. 
Lindley CM, Hirsch JD, O’Neil CV, Transau MC, Gilbert CS, Osterhaus JT. Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1992; 1: 331-340. 
O’Brien BJ, Rusthoven J, Rocchi A i wsp. Impact of chemotherapy-associated nausea and vomiting on patients’ functional status and on cost: survey of five Canadian centres. CMAJ 1993; 149: 113-119. 
Edwards SJ. Prevention and treatment of adverse effect related to chemotherapy for recurrent ovarian cancer. Seminar Oncol Nurs 2003; 19, 3 suppl 1: 19-39. 
Sweeney CW. Understanding peripheral neuropathy in patients with cancer: background and patients assessment. Clin J Oncol Nurs 2002; 6: 163-166. 
Carelle N, Piotto E, Bellanger A, Germanaud J, Thuillier A, Khayat D. Changing patient perceptions of the side effects of cancer chemotherapy. Cancer 2002; 95: 155-163. 
Sun CC, Ramirez PT, Bodurka DC. Quality of life for patients with epithelial ovarian cancer. Nat Clin Pract Oncol 2007; 4: 18-29. 
Ludwig H, Strasser K. Symptomatology of anemia. Semin Oncol 2001; 28, 2 suppl 8: 7-14. 
Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Cancer Inst 1999; 91: 1616-1634. 
Majkowicz M. Wielopoziomowa ocena stanu podmiotowego pacjentów z chorobą nowotworową. Annales Acedemiae Medicae Gedanensis, tom XXXV, supl 2. Wydawnictwo Akademii Medycznej w Gdańsku, Gdańsk 2005. 
Holzner B, Kemmler G, Meraner V i wsp. Fatigue in ovarian carcinoma patients: neglected issue? Cancer 2003; 97: 1564-1572. 
Robson M, Hensley M, Barakat R i wsp. Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy. Gynecol Oncol 2003; 89: 281-287. 
Klee MC, King MT, Machin D, Hansen HH. A clinical model for quality of life assessment in cancer patients receiving chemotherapy. Ann Oncol 2000; 11: 23-30.
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe